Phil Rowlands Healthcare News

Follow[dot]Health is a news alert service for Heathcare and Healthtech. We are following 40K entities across 30M news items - with 1M items added monthly. This is selected healthcare news for Phil Rowlands, which is filed under People. There are 24 news items for this page.

Please provide a valid email address.

Selected Headlines

Date Headline (link) Source
12/7/2019 Takeda to Present Results from the Phase 3 TOURMALINE-AL1 Trial of NINLARO in Patients with Amyloidosis
... studies. Ongoing research and development to investigate potential treatment options for this underserved patient population is critical.” “We look forward to the opportunity to share the data from the TOURMALINE-AL1 trial,” said Phil Rowlands, Head of Oncology Clinical Research and Development, Takeda. “We are confident that sharing our findings ...
Business Wire
12/7/2019 Takeda to Present Results from the Phase 3 TOURMALINE-AL1 Trial of NINLARO in Patients with Amyloidosis
... studies. Ongoing research and development to investigate potential treatment options for this underserved patient population is critical.” “We look forward to the opportunity to share the data from the TOURMALINE-AL1 trial,” said Phil Rowlands , Head of Oncology Clinical Research and Development, Takeda. “We are confident that sharing our findings ...
Financial Times
12/7/2019 Takeda to Present Results from the Phase 3 TOURMALINE-AL1 Trial of NINLARO in Patients with Amyloidosis | Business & Finance | manchestertimes.com
... studies. Ongoing research and development to investigate potential treatment options for this underserved patient population is critical.” “We look forward to the opportunity to share the data from the TOURMALINE-AL1 trial,” said Phil Rowlands, Head of Oncology Clinical Research and Development, Takeda. “We are confident that sharing our findings ...
Business Wire
11/23/2019 Takeda Presents Long-Term Data in ALK+ NSCLC Showing ALUNBRIG® (brigatinib) Continues to Demonstrate Superiority in the First-Line After Two Years of Follow-Up Business Wire
11/23/2019 Takeda Presents Long-Term Data in ALK+ NSCLC Showing ALUNBRIG® (brigatinib) Continues to Demonstrate Superiority in the First-Line After Two Years of Follow-Up Business Wire
11/16/2019 Takeda to Highlight Expanded Portfolio of Products Across Oncology and Hematology at 61st American Society of Hematology (ASH) Annual Meeting blogspot.com
11/16/2019 Takeda to Highlight Expanded Portfolio of Products Across Oncology and Hematology at 61st American Society of Hematology (ASH) Annual Meeting blogspot.com
11/16/2019 Takeda to Highlight Expanded Portfolio of Products Across Oncology and Hematology at 61st American Society of Hematology (ASH) Annual Meeting blogspot.com
11/16/2019 Takeda to Highlight Expanded Portfolio of Products Across Oncology and Hematology at 61st American Society of Hematology (ASH) Annual Meeting blogspot.com
11/15/2019 Takeda to Highlight Expanded Portfolio of Products Across Oncology and Hematology at 61st ... aetoswire.com
11/13/2019 Phase 3 Trial of NINLAROTM (ixazomib) as First Line Maintenance Therapy Met Primary Endpoint in Multiple Myeloma Patients not treated with Stem Cell Transplantation blogspot.com
11/13/2019 Phase 3 Trial of NINLAROTM (ixazomib) as First Line Maintenance Therapy Met Primary Endpoint in Multiple Myeloma Patients not treated with Stem Cell Transplantation blogspot.com
11/13/2019 Phase 3 Trial of NINLAROTM (ixazomib) as First Line Maintenance Therapy Met Primary Endpoint in Multiple Myeloma Patients not treated with Stem Cell Transplantation blogspot.com
11/13/2019 Phase 3 Trial of NINLAROTM (ixazomib) as First Line Maintenance Therapy Met Primary Endpoint in Multiple Myeloma Patients not treated with Stem Cell Transplantation blogspot.com
11/13/2019 Phase 3 Trial of NINLAROTM (ixazomib) as First Line Maintenance Therapy Met Primary Endpoint in Multiple Myeloma Patients not treated with Stem Cell Transplantation blogspot.com
11/13/2019 Phase 3 Trial of NINLAROTM (ixazomib) as First Line Maintenance Therapy Met Primary Endpoint in Multiple Myeloma Patients not treated with Stem Cell Transplantation blogspot.com
11/7/2019 Phase 3 Trial of NINLAROTM (ixazomib) as First Line Maintenance Therapy Met Primary Endpoint in Multiple Myeloma Patients not treated with Stem Cell Transplantation BioSpace
6/5/2019 Takeda Provides Update on TOURMALINE-AL1 Phase 3 Trial in AL Amyloidosis | Business & Finance | heraldchronicle.com Business Wire
5/16/2019 Takeda to Showcase Growing Pipeline and Diversified Portfolio of Oncology Products at Upcoming Scientific Congresses Business Wire